2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

5023 DuoBody-CD3xFLT3 efficiently redirects T cells to eliminate FLT3-positive AML cells in preclinical models

Kim Catharina Martina Santegoets, PhD, Jiske Tiersma2, Jennie Ong3, Debora Lind4, Ellis Gielen5, Hadia Hamdaoui6, Ieva Cesonyte7, Maarten van der Kroef8, Patrick Engelberts9, Kristel Kemper10, David Satijn11, Esther Cornelia Wilhelmina Breij12, Marije Overdijk13
1 Genmab B.V., Utrecht, Netherlands
2 Genmab B.V., Utrecht, Netherlands
3 Genmab B.V., Utrecht, Netherlands
4 Genmab B.V., Utrecht, Netherlands
5 Genmab B.V., Utrecht, Netherlands
6 Genmab B.V., Utrecht, Netherlands
7 Genmab B.V., Utrecht, Netherlands
8 Genmab B.V., Utrecht, Netherlands
9 Genmab B.V., Utrecht, Netherlands
10 Genmab B.V., Utrecht, Netherlands
11 Genmab B.V., Utrecht, Netherlands
12 Genmab B.V., Utrecht, Netherlands
13 Genmab B.V., Utrecht, Netherlands
Introduction
DuoBody®-CD3xFLT3 (GEN3018) is an Fc-inert bispecific antibody (bsAb) designed to induce T-cell-mediated cytotoxicity of FLT3-positive cells by crosslinking CD3 on T cells with the receptor tyrosine kinase FLT3 expressed on tumor cells. It is being developed as a novel therapeutic agent for FLT3-expressing hematologic malignancies, including acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR-MDS). Despite recent advances, AML and MDS represent areas of high unmet medical need, with limited durable responses to current therapies and poor overall survival. This study provides the first insight into the mechanism of action of DuoBody-CD3xFLT3 in preclinical models.

Methods
The mechanism of action of DuoBody-CD3xFLT3 was evaluated using complementary in vitro, in vivo, and ex vivo models. In vitro, T-cell-mediated cytotoxicity, T-cell activation, T-cell proliferation, and cytokine/perforin/granzyme B release were assessed in cocultures of primary human T cells or peripheral blood mononuclear cells with AML cell lines. Cytotoxicity and cytokine secretion in response to DuoBody-CD3xFLT3 treatment were compared with in-house-generated analogs of comparator CD3xFLT3 bsAbs. Antitumor activity and pharmacodynamic effects on human T cells were evaluated in T-cell-humanized NOG mice bearing disseminated MOLM-13 AML cells. Ex vivo antitumor activity was assessed using primary AML blast samples, whereas potential effects on CD34-positive progenitor cells were evaluated using healthy donor bone marrow samples. Lastly, bystander killing of a FLT3-negative cell line and of healthy CD34-positive progenitor cells was assessed in the presence of FLT3-positive tumor cells.

Results
DuoBody-CD3xFLT3 induced potent T-cell-mediated cytotoxicity across multiple AML cell lines, irrespective of FLT3 mutation status, and maintained robust cytotoxicity across all effector-to-target (E:T) ratios tested (i.e., 8:1 to 1:4). Cytotoxicity was accompanied by robust T-cell activation, T-cell proliferation, and concentration-dependent secretion of inflammatory cytokines, granzyme B, and perforin. Relative to analogs of comparator CD3xFLT3 bsAbs, DuoBody-CD3xFLT3 achieved comparable maximal cytotoxicity while inducing one of the lowest levels of cytokine secretion in vitro.

In T-cell-humanized mice bearing disseminated MOLM-13 AML cells, DuoBody-CD3xFLT3 significantly reduced leukemic burden in bone marrow and peripheral blood and prolonged survival. Antitumor activity was associated with increased T-cell numbers in both compartments on Day 7 post-dose.

Ex vivo, DuoBody-CD3xFLT3 induced T-cell activation and T-cell-mediated cytotoxicity of primary AML blasts, while largely sparing healthy CD34-positive hematopoietic progenitor cells. In the presence of FLT3-positive OCI-AML3 cells and T cells, DuoBody-CD3xFLT3 mediated bystander killing of FLT3-negative tumor cells without inducing additional cytotoxicity toward healthy CD34-positive progenitor cells, further supporting its selective antitumor activity in preclinical models.

Conclusion
DuoBody-CD3xFLT3 demonstrated potent and selective antitumor activity across complementary preclinical AML models. DuoBody-CD3xFLT3-induced T-cell-mediated cytotoxicity of FLT3-positive AML cells was associated with T-cell activation and the release of inflammatory cytokines, granzyme B, and perforin, while largely sparing healthy CD34-positive hematopoietic progenitor cells.

 

 

Kim Catharina Martina Santegoets, PhD: Genmab - Current equity holder in publicly-traded company; Genmab - Stock (publicly traded); Genmab - Current Employment